CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 29, 2019--
Seres
Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will
present at the Jefferies 2019 Healthcare Conference in New York, NY on
Wednesday, June 5th at 2:30 p.m. ET.
A live audio webcast of the presentation will be available under the
“Investors and Media” section of Seres’ website. A replay will become
available approximately one hour after the event and will be archived
for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome
therapeutics platform company developing a novel class of biological
drugs that are designed to treat disease by restoring the function of a
dysbiotic microbiome, where the state of bacterial diversity and
function is imbalanced. Seres’ SER-287 program has obtained Fast Track
and Orphan Drug designation from the U.S. Food and Drug Administration
and is being evaluated in a Phase 2b study in patients with active
mild-to-moderate ulcerative colitis. Seres’ SER-109 program has obtained
Breakthrough Therapy and Orphan Drug designations from the FDA and is in
Phase 3 development for recurrent C. Difficile infection. Seres
is also developing SER-401 in a Phase 1b study in patients with
metastatic melanoma. For more information, please visit www.serestherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005917/en/
Source: Seres Therapeutics, Inc.
IR or PR Contact:
Carlo Tanzi, Ph.D.
Investor Relations
ctanzi@serestherapeutics.com